Background
Vessel‐wall enhancement (VWE) on black‐blood MRI (BB MRI) has been proposed as an imaging marker for a higher risk of rupture and associated with wall inflammation. Whether VWE is causally linked to inflammation or rather induced by flow phenomena has been a subject of debate.
Purpose
To study the effects of slow flow, spatial resolution, and motion‐sensitized driven equilibrium (MSDE) preparation on signal intensities in BB MRI of patient‐specific aneurysm flow models.
Study Type
Prospective.
Subjects/Flow Aneurysm Model/Virtual Vessels
Aneurysm flow models based on 3D rotational angiography datasets of three patients with intracranial aneurysms were 3D printed and perfused at two different flow rates, with and without Gd‐containing contrast agent.
Field Strength/Sequence
Variable refocusing flip angle 3D fast‐spin echo sequence at 3 T with and without MSDE with three voxel sizes ((0.5 mm)3, (0.7 mm)3, and (0.9 mm)3); time‐resolved with phase‐contrast velocity‐encoding 3D spoiled gradient echo sequence (4D flow MRI).
Assessment
Three independent observers performed a qualitative visual assessment of flow patterns and signal enhancement. Quantitative analysis included voxel‐wise evaluation of signal intensities and magnitude velocity distributions in the aneurysm.
Statistical Tests
Kruskal–Wallis test, potential regressions.
Results
A hyperintense signal in the lumen and adjacent to the aneurysm walls on BB MRI was colocalized with slow flow. Signal intensities increased by a factor of 2.56 ± 0.68 (P < 0.01) after administering Gd contrast. After Gd contrast administration, the signal was suppressed most in conjunction with high flows and with MSDE (2.41 ± 2.07 for slow flow without MSDE, and 0.87 ± 0.99 for high flow with MSDE). A clear result was not achieved by modifying the spatial resolution .
Data Conclusions
Slow‐flow phenomena contribute substantially to aneurysm enhancement and vary with MRI parameters. This should be considered in the clinical setting when assessing VWE in patients with an unruptured aneurysm.
Evidence Level
2
Technical Efficacy
Stage 2